{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:40:05Z","timestamp":1794336005593,"version":"4.9.0"},"reference-count":25,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2025.2034","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:16:07Z","timestamp":1753179367000},"page":"1-7","source":"Crossref","is-referenced-by-count":5,"title":["Real\u2011world effectiveness and safety of cefiderocol in critically ill patients with MDR Gram\u2011negative infections: Results from a retrospective study"],"prefix":"10.3892","volume":"23","author":[{"given":"Andrea","family":"Marino","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, I\u201195123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuele","family":"Rullo","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, I\u201198122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylenia","family":"Russotto","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, I\u201198122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Visicaro","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, I\u201198122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Micali","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, I\u201198122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagiovanna","family":"Coco","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, I\u201195123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Campanella","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, I\u201195123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellican\u00f2","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, I\u201198122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Iacobello","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, \u2018Cannizzaro\u2019 Hospital for Emergencies, I\u201195126 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Nunnari","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Catania, I\u201195123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"issue":"21","key":"key20250903134314_b1-BR-23-4-02034","doi-asserted-by":"publisher","DOI":"10.3390\/epidemiologia6020021","article-title":"The Global burden of multidrug-resistant bacteria","volume":"6","author":"Marino","year":"2025","journal-title":"Epidemiologia (Basel)"},{"key":"key20250903134314_b2-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s15010-024-02423-6","article-title":"Bacteremic nosocomial pneumonia caused by Gram-negative bacilli: Results from the nationwide ALARICO study in Italy","volume":"53","author":"Tiseo","year":"2025","journal-title":"Infection"},{"key":"key20250903134314_b3-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s40121-024-01016-y","article-title":"Use of cefiderocol in adult patients: Descriptive analysis from a prospective, multicenter, cohort study","volume":"13","author":"Giacobbe","year":"2024","journal-title":"Infect Dis Ther"},{"key":"key20250903134314_b4-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"2318","key":"key20250903134314_b5-BR-23-4-02034","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14202318","article-title":"Issues with cefiderocol testing: Comparing commercial methods to broth microdilution in iron-depleted medium-analyses of the performances, ATU, and trailing effect according to EUCAST initial and revised interpretation criteria","volume":"14","author":"Stracquadanio","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"e0061723","key":"key20250903134314_b6-BR-23-4-02034","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00617-23","article-title":"Role of transcriptomic and genomic analyses in improving the comprehension of cefiderocol activity in Acinetobacter baumannii","volume":"9","author":"Stracquadanio","year":"2024","journal-title":"mSphere"},{"key":"key20250903134314_b7-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"key20250903134314_b8-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"key20250903134314_b9-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"key20250903134314_b10-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"key20250903134314_b11-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key20250903134314_b12-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jmii.2021.08.012","article-title":"In vitro activity of cefiderocol, cefepime\/enmetazobactam, cefepime\/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020","volume":"55","author":"Liu","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"key20250903134314_b13-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/1120009X.2022.2031471","article-title":"Activity of ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol and comparators against Gram-negative organisms causing bloodstream infections in Northern Italy (2019\u20132021): emergence of complex resistance phenotypes","volume":"34","author":"Bianco","year":"2022","journal-title":"J Chemother"},{"key":"key20250903134314_b14-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/QCO.0000000000000635","article-title":"Treatment of multidrug-resistant Gram-negative skin and soft tissue infections","volume":"33","author":"Jabbour","year":"2020","journal-title":"Curr Opin Infect Dis"},{"issue":"746","key":"key20250903134314_b15-BR-23-4-02034","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12040746","article-title":"Cefiderocol efficacy in a real-life setting: Single-centre retrospective study","volume":"12","author":"Palermo","year":"2023","journal-title":"Antibiotics (Basel)"},{"issue":"ofae631.1645","key":"key20250903134314_b16-BR-23-4-02034","article-title":"P-1475. Real-world effectiveness and safety of cefiderocol in the treatment of patients with serious Gram-negative bacterial infections: Results of the PROVE chart review study","volume":"12 (Suppl 1)","author":"Clancy","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"dlab188","key":"key20250903134314_b17-BR-23-4-02034","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrobial Resist"},{"issue":"239","key":"key20250903134314_b18-BR-23-4-02034","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02950-2","article-title":"Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019- results from a systematic review and meta-analysis","volume":"24","author":"Bauer","year":"2020","journal-title":"Crit Care"},{"key":"key20250903134314_b19-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.37201\/req\/s02.04.2022","article-title":"Pharmacokinetics\/pharmacodynamics and tolerability of cefiderocol in the clinical setting","volume":"35 (Suppl 2)","author":"Azanza Perea","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"key20250903134314_b20-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jgar.2021.02.004","article-title":"Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomised controlled trials","volume":"24","author":"Hsueh","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"key20250903134314_b21-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/14787210.2020.1813022","article-title":"Global travel and Gram-negative bacterial resistance; implications on clinical management","volume":"19","author":"Theriault","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"key20250903134314_b22-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s40121-022-00598-9","article-title":"Outcomes with cefiderocol treatment in patients with Bacteraemia enrolled into prospective phase 2 and phase 3 randomised clinical studies","volume":"11","author":"Paterson","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"889","key":"key20250903134314_b23-BR-23-4-02034","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05870-w","article-title":"Investigator-driven randomised controlled trial of cefiderocol versus standard therapy for healthcare-associated and hospital-acquired Gram-negative bloodstream infection: Study protocol (the GAME CHANGER trial): Study protocol for an open-label, randomised controlled trial","volume":"22","author":"Wright","year":"2021","journal-title":"Trials"},{"key":"key20250903134314_b24-BR-23-4-02034","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1097\/INF.0000000000004347","article-title":"Use of cefiderocol in the management of children with infection or colonization with multi-drug resistant Gram-negative bacteria: A retrospective, single-center case series","volume":"43","author":"Schmid","year":"2024","journal-title":"Pediatr Infect Dis J"},{"issue":"6814","key":"key20250903134314_b25-BR-23-4-02034","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136814","article-title":"Unveiling the secrets of Acinetobacter baumannii: Resistance, current treatments, and future innovations","volume":"25","author":"Marino","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:43:17Z","timestamp":1756896197000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2025.2034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2025.2034","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]}}}